Video

Options in Unresectable Metastatic Colorectal Cancer

Patient follow-up depends upon the stage of the colorectal cancer (CRC) as well as whether they are actively receiving treatment, radiation, or planning for surgery, states Cathy Eng, MD. A patient with early stage disease who has already had surgery is typically then treated with 6 months of chemotherapy. Communicating with patients regarding the extent of their treatment is important so that they can more easily make personal decisions, says Eng.

Metastatic CRC cannot be surgically cured, and chemotherapy is continued indefinitely for those who tolerate treatment and have appropriate laboratory values. These patients have incurable residual disease, and chemotherapy is given to prolong their lives, comments Eng. Individuals often need treatment breaks, which are typically given for 2 to 6 weeks.

It is difficult to tell patients that you cannot cure their disease, says John L. Marshall, MD. Oncologists should explain that the goal of therapy is to maintain a high quality of life, while also controlling the disease and minimizing toxicities. There is often a clinical trial available, adds Marshall.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Aparna Parikh, MD
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.